{"id":20132,"date":"2024-07-15T15:33:00","date_gmt":"2024-07-15T19:33:00","guid":{"rendered":"https:\/\/www.ices.on.ca\/?post_type=journal_article&p=20132"},"modified":"2024-08-12T15:43:02","modified_gmt":"2024-08-12T19:43:02","slug":"pomalidomide-use-and-kidney-outcomes-in-patients-with-relapsed-refractory-multiple-myeloma-and-chronic-kidney-disease","status":"publish","type":"journal_article","link":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/pomalidomide-use-and-kidney-outcomes-in-patients-with-relapsed-refractory-multiple-myeloma-and-chronic-kidney-disease\/","title":{"rendered":"Pomalidomide use and kidney outcomes in patients with relapsed\/refractory multiple myeloma and chronic kidney disease: a real-world, population-based cohort study"},"content":{"rendered":"

Background<\/strong> \u2014 Pomalidomide-based regimens are the cornerstone of treatment for relapsed\/refractory MM (RRMM). Despite the high incidence of chronic kidney disease (CKD) in RRMM, individuals with advanced CKD have been excluded from phase II\/III RCTs, creating a gap in our understanding of the effects of pomalidomide use in patients with RRMM complicated with advanced CKD. We undertook a cohort to study to understand the efficacy safety of pomalidomide-based regimens among patients with CKD using real-world data.<\/p>\n

Methods<\/strong> \u2014 Population-based, cohort study of patients \u2265 18 years with RRMM treated with pomalidomide in Ontario, Canada. Primary outcome was all-cause mortality. Secondary outcomes were time-to-major adverse kidney events (MAKE), time-to-next treatment, kidney response and safety.<\/p>\n

Results<\/strong> \u2014 Total 748 patients with RRMM utilizing pomalidomide were included; 440 had preserved kidney function, 210 had moderate CKD (eGFR 30-59 mL\/min\/1.73m2), and 98 had advanced CKD (eGFR < 30 mL\/min\/1.73m2). Mean age was 70.2 years, 43.3% were women. Patients with advanced CKD had a higher risk of all-cause mortality compared to the preserved kidney function group (aHR 1.37, 95% CI 1.06, 1.78). MAKE was higher in advanced CKD (aHR 1.70, 95% CI 1.03, 2.35). Kidney response was similar between moderate and severe CKD groups (aOR 1.04, 95%, CI 0.56-1.90). Safety outcomes were similar between groups.<\/p>\n

Conclusions<\/strong> \u2014 Patients with advanced CKD and RRMM on pomalidomide-based regimens exhibited reduced survival and a higher risk for MAKE. However, the probability of experiencing some degree of kidney recovery is 50% in both moderate and severe CKD, with comparable safety outcomes.<\/p>\n","protected":false},"excerpt":{"rendered":"

Background \u2014 Pomalidomide-based regimens are the cornerstone of treatment for relapsed\/refractory MM (RRMM). Despite the high incidence of chronic kidney disease (CKD) in RRMM, individuals with advanced CKD have been excluded from phase II\/III RCTs, creating a gap in our understanding of the effects of pomalidomide use in patients with RRMM complicated with advanced CKD. […]<\/p>\n","protected":false},"template":"","migration-helper-automated":[],"migration-manual":[],"topic":[38,49,56],"migration-helper-qa-sample-set":[],"class_list":["post-20132","journal_article","type-journal_article","status-publish","hentry","topic-cancer-and-cancer-screening","topic-kidney-disease","topic-pharmacoepidemiology-and-drug-safety"],"acf":{"citation":"Meraz-Munoz A, Mian H, Kirkwood D, Jeyakumar N, McCurdy A, Tangri N, Saskin R, Leung N, Wald R, Kitchlu A. Clin Lymphoma Myeloma Leuk<\/em>. 2024; S2152-2650(24)00265-9. Epub 2024 Jul 15.","source_url":"https:\/\/doi.org\/10.1016\/j.clml.2024.07.007","ices_scientist":[1360,1123],"site":[6737],"research_program":[6743],"news_release":"","journal_article":"","atlas":"","research_report":"","infographic":"","video":"","downloads":null,"links":null,"sitecore_item_id":"","sitecore_item_name":"","sitecore_field_values":"","previous_url":""},"yoast_head":"\nICES | Pomalidomide use and kidney outcomes in patients with relapsed\/refractory multiple myeloma and chronic kidney disease: a real-world, population-based cohort study<\/title>\n<meta name=\"description\" content=\"Background \u2014 Pomalidomide-based regimens are the cornerstone of treatment for relapsed\/refractory MM (RRMM). Despite the high incidence of chronic kidney\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/pomalidomide-use-and-kidney-outcomes-in-patients-with-relapsed-refractory-multiple-myeloma-and-chronic-kidney-disease\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ICES | Pomalidomide use and kidney outcomes in patients with relapsed\/refractory multiple myeloma and chronic kidney disease: a real-world, population-based cohort study\" \/>\n<meta property=\"og:description\" content=\"Background \u2014 Pomalidomide-based regimens are the cornerstone of treatment for relapsed\/refractory MM (RRMM). Despite the high incidence of chronic kidney\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/pomalidomide-use-and-kidney-outcomes-in-patients-with-relapsed-refractory-multiple-myeloma-and-chronic-kidney-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"ICES\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ICESOntario\/\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-12T19:43:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/pomalidomide-use-and-kidney-outcomes-in-patients-with-relapsed-refractory-multiple-myeloma-and-chronic-kidney-disease\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/pomalidomide-use-and-kidney-outcomes-in-patients-with-relapsed-refractory-multiple-myeloma-and-chronic-kidney-disease\\\/\",\"name\":\"ICES | Pomalidomide use and kidney outcomes in patients with relapsed\\\/refractory multiple myeloma and chronic kidney disease: a real-world, population-based cohort study\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\"},\"datePublished\":\"2024-07-15T19:33:00+00:00\",\"dateModified\":\"2024-08-12T19:43:02+00:00\",\"description\":\"Background \u2014 Pomalidomide-based regimens are the cornerstone of treatment for relapsed\\\/refractory MM (RRMM). Despite the high incidence of chronic kidney\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/pomalidomide-use-and-kidney-outcomes-in-patients-with-relapsed-refractory-multiple-myeloma-and-chronic-kidney-disease\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/pomalidomide-use-and-kidney-outcomes-in-patients-with-relapsed-refractory-multiple-myeloma-and-chronic-kidney-disease\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/pomalidomide-use-and-kidney-outcomes-in-patients-with-relapsed-refractory-multiple-myeloma-and-chronic-kidney-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Journal Articles\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Pomalidomide use and kidney outcomes in patients with relapsed\\\/refractory multiple myeloma and chronic kidney disease: a real-world, population-based cohort study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"name\":\"ICES\",\"description\":\"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\"},\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\",\"name\":\"ICES\",\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"contentUrl\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"width\":\"676\",\"height\":\"618\",\"caption\":\"ICES\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ICESOntario\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ices-research-institute\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ICES | Pomalidomide use and kidney outcomes in patients with relapsed\/refractory multiple myeloma and chronic kidney disease: a real-world, population-based cohort study","description":"Background \u2014 Pomalidomide-based regimens are the cornerstone of treatment for relapsed\/refractory MM (RRMM). Despite the high incidence of chronic kidney","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/pomalidomide-use-and-kidney-outcomes-in-patients-with-relapsed-refractory-multiple-myeloma-and-chronic-kidney-disease\/","og_locale":"fr_FR","og_type":"article","og_title":"ICES | Pomalidomide use and kidney outcomes in patients with relapsed\/refractory multiple myeloma and chronic kidney disease: a real-world, population-based cohort study","og_description":"Background \u2014 Pomalidomide-based regimens are the cornerstone of treatment for relapsed\/refractory MM (RRMM). Despite the high incidence of chronic kidney","og_url":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/pomalidomide-use-and-kidney-outcomes-in-patients-with-relapsed-refractory-multiple-myeloma-and-chronic-kidney-disease\/","og_site_name":"ICES","article_publisher":"https:\/\/www.facebook.com\/ICESOntario\/","article_modified_time":"2024-08-12T19:43:02+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/pomalidomide-use-and-kidney-outcomes-in-patients-with-relapsed-refractory-multiple-myeloma-and-chronic-kidney-disease\/","url":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/pomalidomide-use-and-kidney-outcomes-in-patients-with-relapsed-refractory-multiple-myeloma-and-chronic-kidney-disease\/","name":"ICES | Pomalidomide use and kidney outcomes in patients with relapsed\/refractory multiple myeloma and chronic kidney disease: a real-world, population-based cohort study","isPartOf":{"@id":"https:\/\/www.ices.on.ca\/fr\/#website"},"datePublished":"2024-07-15T19:33:00+00:00","dateModified":"2024-08-12T19:43:02+00:00","description":"Background \u2014 Pomalidomide-based regimens are the cornerstone of treatment for relapsed\/refractory MM (RRMM). Despite the high incidence of chronic kidney","breadcrumb":{"@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/pomalidomide-use-and-kidney-outcomes-in-patients-with-relapsed-refractory-multiple-myeloma-and-chronic-kidney-disease\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/pomalidomide-use-and-kidney-outcomes-in-patients-with-relapsed-refractory-multiple-myeloma-and-chronic-kidney-disease\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/pomalidomide-use-and-kidney-outcomes-in-patients-with-relapsed-refractory-multiple-myeloma-and-chronic-kidney-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ices.on.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Journal Articles","item":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/"},{"@type":"ListItem","position":3,"name":"Pomalidomide use and kidney outcomes in patients with relapsed\/refractory multiple myeloma and chronic kidney disease: a real-world, population-based cohort study"}]},{"@type":"WebSite","@id":"https:\/\/www.ices.on.ca\/fr\/#website","url":"https:\/\/www.ices.on.ca\/fr\/","name":"ICES","description":"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE","publisher":{"@id":"https:\/\/www.ices.on.ca\/fr\/#organization"},"alternateName":"Institute for Clinical Evaluative Sciences","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ices.on.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ices.on.ca\/fr\/#organization","name":"ICES","alternateName":"Institute for Clinical Evaluative Sciences","url":"https:\/\/www.ices.on.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","contentUrl":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","width":"676","height":"618","caption":"ICES"},"image":{"@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ICESOntario\/","https:\/\/www.linkedin.com\/company\/ices-research-institute\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article\/20132","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article"}],"about":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/types\/journal_article"}],"acf:post":[{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/research_program\/6743"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/site\/6737"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1123"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1360"}],"wp:attachment":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/media?parent=20132"}],"wp:term":[{"taxonomy":"migration-helper-automated","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-automated?post=20132"},{"taxonomy":"migration-manual","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-manual?post=20132"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/topic?post=20132"},{"taxonomy":"migration-helper-qa-sample-set","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-qa-sample-set?post=20132"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}